A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Brain disorders; Friedreich's ataxia; Malignant melanoma; Mitochondrial disorders; Ocular inflammation; Ocular pain
- Focus Pharmacokinetics
- Sponsors Reata Pharmaceuticals
- 16 Mar 2020 Status changed from recruiting to completed.
- 18 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 28 Aug 2019 Status changed from not yet recruiting to recruiting.